Navigation Links
Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
Date:3/5/2009

udy was to demonstrate the efficacy of three treatments of Isolagen Therapy on one side of the face as compared with placebo treatment on the other side of the face for the treatment of moderate to severe acne scars. The primary efficacy endpoints are measured four months following the last study treatment, using the following co-primary endpoints:

-- Patient Live Acne Scarring Assessment: The Patients' live assessment of the acne scarring of each cheek, using a 5point assessment scale, with a response defined as a 2-point improvement as compared to baseline, and an

-- Evaluator Live Acne Scar Assessment: The Evaluators' live assessment of the acne scarring of the treatment area on each cheek, using a 5-point assessment scale and photoguide, with a response defined as a 1-point improvement as compared to baseline.

Isolagen's Phase II/III study for moderate to severe acne scars was conducted under an FDA Investigational New Drug Application. Although statistically significant, these results do not guarantee approval of a commercial license or a labeling claim for this indication. The Company believes that to ultimately obtain FDA approval with respect to the acne scar indication, the Company will require FDA concurrence with the use of the Company's Evaluator Live Acne Scar Assessment scale, which the Company developed specifically for use in this study and which has not been previously used in a clinical trial. Further, if the Company obtains this concurrence from the FDA, then the Company will also require, at a minimum, one additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure.

Update Regarding Isolagen's Cash Position and the Biologics License Application for Wrinkles/Nasolabial Folds

Isolagen currently estimates that its unrestricted, available cash resources will allow the Company to continue in operation for approximat
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
2. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... According to a new market ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... of 10.1% from 2014 to 2020. Biological ... used in the treatment and prevention of various diseases ... medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
(Date:9/1/2014)... 1, 2014 Research and Markets ... Minimally-Invasive Biomarkers in Alzheimer,s Disease: A Comprehensive Analysis and ... report to their offering. This report ... developments relating to early-stage minimally-invasive biomarkers in Alzheimer,s disease, ... and candidates in the AD drug pipeline, and applicable ...
Breaking Medicine Technology:CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2
... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 (vinorelbine injectable emulsion). , ... , ... ... ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) a biotechnology company focused on the development of small-molecule ... fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance ... ... , ...
Cached Medicine Technology:ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 2Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 3Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 4Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 5Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 6Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 7Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 8Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 9Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 10Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance 11
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many ... of employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, ... to 10% off, on these useful items. , ... 20 different kinds of high end monitoring programs on ... companies of all sizes. With its high end programs, ...
(Date:9/2/2014)... A simple awareness campaign in general practice identifies new ... at ESC Congress today by Professor Jean-Marc Davy from ... the most common cardiac arrhythmia. It multiplies the risk ... of stroke risk by five-fold. Similarly, AF is responsible ... AF is often overlooked and diagnosed too late. In ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 ... for about a decade, primarily to help people ... time, there are three developed systems,” says Dana ... approaches substantively differ, the goals are much the ... support of some type of harmonica.” , The ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... new study finds that, despite efforts in the last ... significantly less likely than white patients to receive therapy ... study conclude that efforts to close treatment gaps initiated ... The report appears in the February 15, 2008 issue ...
... Conn., Jan. 6 Therap Services, the leading,provider ... has announced the promotion of Allison Dudo to ... responsibility of,providing help and technical guidance to users ... key part of our success, and we were ...
... heavily than male peers, field study finds , , SUNDAY, ... of college drinking behavior shows that parties with drinking ... parties encourage college women to drink more heavily than ... drinking have relied largely on individual behavior and self-reports ...
... Year,s,resolution is to lose weight, calcium and dairy can help, ... Science Hawley,Almstedt and her student Alexandra Hybki. The everyday nutrients ... down this year., People on fad diets or extreme ... foods are high in fat. Some dieters go,so far as ...
... Holdings, Inc. President Robert Oswald provides a shareholder,update., ... as we opened 5 new,locations across Canada, including the ... were fortunate to have our Official Spokesperson,for Canada, Mr. ... opening,events for our new locations. I was very pleased ...
... radiation after early-stage disease is removed, researchers say , FRIDAY, ... have not yet spread contain cells with a predisposition to ... just because a cancer has not yet spread doesn,t mean ... warned researchers at the Salk Institute for Biological Studies in ...
Cached Medicine News:Health News:Racial disparities persist in cancer care 2Health News:Therap Services Promotes Allison Dudo to Assistant Director of Training 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:Milk Does a Body and a Waistline Good 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 2Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 3Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 4Health News:HearAtLast Holdings, Inc. Provides Shareholder Update 5Health News:Localized Breast Cancer Cells Have Potential to Spread 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: